FDA Accepts REMOXY® NDA for Review, Sets PDUFA Date of August 7, 2018 – GlobeNewswire (press release)

This post was originally published on this site

FDA Accepts REMOXY® NDA for Review, Sets PDUFA Date of August 7, 2018
GlobeNewswire (press release)
REMOXY ER is an abuse-deterrent, extended-release, capsule formulation of oxycodone (CII), a prescription drug for severe pain. REMOXY ER has a thick, sticky, high-viscosity capsule formulation designed to deter unapproved routes of drug administration

and more »

Related Post